Xiamen Amoytop Biotech Future Growth
Future criteria checks 6/6
Xiamen Amoytop Biotech is forecast to grow earnings and revenue by 30.4% and 28.2% per annum respectively. EPS is expected to grow by 30.3% per annum. Return on equity is forecast to be 31.1% in 3 years.
Key information
30.4%
Earnings growth rate
30.3%
EPS growth rate
Biotechs earnings growth | 34.3% |
Revenue growth rate | 28.2% |
Future return on equity | 31.1% |
Analyst coverage | Low |
Last updated | 25 Apr 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 4,917 | 1,403 | 1,122 | 1,351 | 4 |
12/31/2025 | 3,729 | 1,028 | 836 | 1,005 | 5 |
12/31/2024 | 2,830 | 756 | 525 | 794 | 4 |
3/31/2024 | 2,226 | 600 | 241 | 569 | N/A |
12/31/2023 | 2,100 | 555 | 224 | 512 | N/A |
9/30/2023 | 1,843 | 456 | 275 | 519 | N/A |
6/30/2023 | 1,716 | 356 | -11 | 262 | N/A |
3/31/2023 | 1,601 | 314 | 97 | 302 | N/A |
12/31/2022 | 1,527 | 287 | 144 | 363 | N/A |
9/30/2022 | 1,466 | 254 | 47 | 287 | N/A |
6/30/2022 | 1,378 | 243 | 71 | 286 | N/A |
3/31/2022 | 1,262 | 204 | 50 | 262 | N/A |
12/31/2021 | 1,132 | 181 | 44 | 235 | N/A |
9/30/2021 | 1,043 | 168 | 45 | 208 | N/A |
6/30/2021 | 904 | 142 | 3 | 164 | N/A |
3/31/2021 | 822 | 128 | 0 | 135 | N/A |
12/31/2020 | 794 | 117 | -26 | 93 | N/A |
9/30/2020 | 762 | 98 | 25 | 117 | N/A |
6/30/2020 | 771 | 95 | 60 | 121 | N/A |
3/31/2020 | 771 | 86 | 63 | 118 | N/A |
12/31/2019 | 730 | 64 | 78 | 123 | N/A |
9/30/2019 | 665 | 58 | 61 | 100 | N/A |
12/31/2018 | 448 | 16 | 75 | 89 | N/A |
12/31/2017 | 323 | 5 | N/A | -11 | N/A |
12/31/2016 | 280 | 29 | N/A | 42 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688278's forecast earnings growth (30.4% per year) is above the savings rate (2.9%).
Earnings vs Market: 688278's earnings (30.4% per year) are forecast to grow faster than the CN market (24.4% per year).
High Growth Earnings: 688278's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 688278's revenue (28.2% per year) is forecast to grow faster than the CN market (14.6% per year).
High Growth Revenue: 688278's revenue (28.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688278's Return on Equity is forecast to be high in 3 years time (31.1%)